Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $68 to $65.